Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - dabrafenibum - hartkapseln - dabrafenibum 50 mg ut dabrafenibi mesilas, cellulosum microcristallinum, magnesii stearas, silica colloidalis anhydrica, kapselhülle: hypromellosum, e 171, e 172 (rubrum), drucktinte: lacca, e 172 (nigrum), propylenglycolum, ammonii hydroxidum, pro capsula. - onkologikum - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - dabrafenibum - hartkapseln - dabrafenibum 75.0 mg ut dabrafenibi mesilas, cellulosum microcristallinum, magnesii stearas, silica colloidalis anhydrica, kapselhülle: hypromellosum, e 171, e 172 (rubrum), drucktinte: lacca, e 172 (nigrum), propylenglycolum, ammonii hydroxidum, pro capsula. - onkologikum - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - trametinibum - filmtabletten - trametinibum 0.5 mg ut trametinibi dimethylis sulfoxidi solvatum, mannitolum, cellulosum microcristallinum, hypromellosum, carmellosum natricum conexum, natrii laurilsulfas, silica colloidalis hydrica, magnesii stearas, Überzug: hypromellosum, macrogolum, e 171, e 172 (flavum), pro compresso obducto corresp. natrium 0.199 mg. - melanom, nicht-kleinzelliges lungenkarzinom - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - trametinibum - filmtabletten - trametinibum 2 mg ut trametinibi dimethylis sulfoxidi solvatum, mannitolum, cellulosum microcristallinum, hypromellosum, carmellosum natricum conexum, natrii laurilsulfas, silica colloidalis hydrica, magnesii stearas, Überzug: hypromellosum, macrogolum, polysorbatum 80, e 171, e 172 (rubrum), pro compresso obducto corresp. natrium 0.232 mg. - melanom, nicht-kleinzelliges lungenkarzinom - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

pierre fabre pharma sa - encorafenibum - hartkapseln - encorafenibum 50 mg, excipiens pro kapsel. - melanom mit braf-v600-mutation in kombination mit binimetinib,; metastasiertes kolorektalkarzinom (crc) mit einer braf-v600e-mutation in kombination mit cetuximab - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

pierre fabre pharma sa - encorafenibum - hartkapseln - encorafenibum 75 mg, excipiens pro kapsel. - melanom mit braf-v600-mutation in kombination mit binimetinib,; metastasiertes kolorektalkarzinom (crc) mit einer braf-v600e-mutation in kombination mit cetuximab - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

pierre fabre pharma sa - binimetinibum - filmtabletten - binimetinibum 15 mg, excipiens pro compresso obducto. - melanom mit braf-v600-mutation in kombination mit encorafenib - synthetika

Europäische Union - Deutsch - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - ipilimumab - melanoma; carcinoma, renal cell; carcinoma, non-small-cell lung; mesothelioma, malignant; colorectal neoplasms - antineoplastische mittel - melanomayervoy as monotherapy or combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older (see section 4.  yervoy in combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. relative to nivolumab monotherapy, an increase in progression-free survival (pfs) and overall survival (os) for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression (see sections 4. 4 und 5. renal cell carcinoma (rcc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (see section 5. non-small cell lung cancer (nsclc)yervoy in combination with nivolumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. malignant pleural mesothelioma (mpm)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. mismatch repair deficient (dmmr) or microsatellite instability-high (msi-h) colorectal cancer (crc)yervoy in combination with nivolumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy (see section 5. oesophageal squamous cell carcinoma (oscc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%.

Europäische Union - Deutsch - EMA (European Medicines Agency)

novartis europharm limited - trametinib - melanom - antineoplastische mittel - melanomatrametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 und 5. trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior braf inhibitor therapy (see section 5. adjuvant treatment of melanomatrametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with stage iii melanoma with a braf v600 mutation, following complete resection. non-small cell lung cancer (nsclc)in kombination mit trametinib dabrafenib ist angezeigt zur behandlung von erwachsenen patienten mit fortgeschrittenem nicht-kleinzelligem lungenkrebs mit einer braf-v600-mutation.

Österreich - Deutsch - AGES (Agentur für Gesundheit und Ernährungssicherheit)

sanova pharma gmbh - primidon - primidon